An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of editing human embryos to make disease-free children.

With the demand for human donor organs desperately outstripping supply, scientists are working to see if genetically edited pig organs can bridge the gap.